Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients

(2010) M. Zangari et al.   HAEMATOLOGICA

Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma

(2009) Sarah Deleu et al.   CANCER RESEARCH

Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide

(2009) Monica De Matteo et al.   LEUKEMIA RESEARCH

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

(2008) Angela Pennisi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

(2008) I Breitkreutz et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE